Sunday global outlook · Friday closes · Monday confirmation map

Aman's Global Market Intelligence — 2026-10-04

Generated 08:30 CEST (Europe/Rome) · Research cutoff 08:30 CEST / 06:30 UTC. Cash-market dashboard uses Friday, October 2 closes. At this Sunday cutoff, CME U.S. equity futures had not opened for the week (the regular Globex week begins Sunday evening U.S. time); no stale Friday settlement is presented as a live weekend signal.

NEUTRAL → CAUTIOUS RISK-ON — TECH MOMENTUM, BUT 5.28% 10Y CAPS UPSIDE

Friday's weak payroll print reduced near-term Fed-hike pressure and lifted growth equities, yet long yields rose, oil remains above $90/$100, and Nasdaq breadth was not clean. Monday's best setup is confirmation in liquid AI leaders—not blanket risk-taking.

Executive dashboard

S&P 5007,722.72+0.73% Fri · −0.27% week
Nasdaq Composite27,190.86+1.19% · +0.45% week
Dow51,176.96+0.49% · −1.26% week
Russell 20002,832.89+0.94% Fri
VIX15.31−6.59% Fri · Cboe
U.S. 2Y / 10Y4.83% / 5.28%Friday close
Dollar index101.93−0.17% Fri
WTI / Brent$91.11 / $102.25Friday futures references
Gold futures$4,162.30−0.95% Fri
Nikkei / Hang Seng68,309 / 23,972−0.94% / −2.60%
STOXX 600 / Euro STOXX 50631.35 / 6,238.50+0.75% / +1.02%
DAX / FTSE 10025,231 / 10,462+1.17% / +0.32%
Weekend risk proxyBTC ~$84,902+0.16% · Oct. 4 01:57 ET snapshot

Cross-checks: Reuters U.S. close, Reuters global close, CNN world-market board, MarketWatch, official Cboe VIX history and Treasury curve. Bitcoin is a continuously traded risk proxy, not an equity-futures substitute.

1 · Soft labor, not soft long yields

September payrolls rose 29,000; unemployment was 4.2%, wages +0.1% m/m and +3.0% y/y, and July/August were revised down 60,000 combined. The 10-year nevertheless ended near 5.28%. BLS · Treasury

2 · AI remains the earnings transmission chain

Reuters says Q3 S&P earnings are expected to grow more than 30% y/y; the key question is hyperscaler capex revisions. That supports compute/connectivity but raises financing, ROI and concentration risk. Reuters week ahead

3 · Weekend governance risk

A former OpenAI safety employee criticized the company's launch culture; OpenAI said it pauses or holds back models when needed. This is not a Monday earnings event, but it reinforces regulatory/reputational risk across the AI stack. Reuters, Oct. 3

Global outlook and market drivers

Macro, rates and geopolitics

  • Fed: Friday reduced the implied chance of an October hike to 22.7%, per CME data cited by Reuters, but the curve remains steep (2Y 4.83%, 10Y 5.28%). Wednesday's minutes can reprice the path. Reuters · Fed
  • Growth: 29,000 payrolls and 45,000 average monthly growth over the prior year are a caution signal, even if slower wages ease inflation pressure. BLS
  • Oil: Brent above $100 keeps inflation/geopolitical tail risk alive. Any weekend escalation can gap equities and invalidate Friday levels before stops execute.
  • Europe: Friday's +0.75% STOXX 600 rebound followed a difficult bond week; France/Germany spread stress and imported energy costs remain watchpoints. Reuters global wrap

Rotation, breadth and coming earnings

  • U.S. breadth: advancers led 1.67:1 on NYSE and 1.34:1 on Nasdaq, but Nasdaq still printed 224 new lows versus 57 new highs. Risk-on was constructive, not unqualified. Reuters
  • Leadership: NVDA +1.3% and TSLA +4.7% were major S&P supports; storage names WDC/STX fell about 10% on prospective Toshiba capacity. This is selective AI rotation.
  • Earnings: PepsiCo and Delta are the prominent early-Q3 reporters next week; major banks broaden the season the following week. Reuters
  • Seasonality: historically strong Q4 statistics are context, not a signal; yields, oil, AI funding and Nov. 3 U.S. midterms can dominate.
RegionLatest cash signalSunday interpretationMonday test
U.S.All four major indices rose Friday; Nasdaq led.Cautiously constructive, but high yields and weak new-high/new-low breadth argue against chasing.S&P hold 7,666; Nasdaq leadership plus stable 10Y/oil.
EuropeSTOXX 600 +0.75%; DAX +1.17%.Relief bounce amid sovereign-yield and energy stress.Credit/spread stability and follow-through beyond Friday.
AsiaNikkei −0.94%; HSI −2.60%; mainland China holiday reference remains Sept. 30.Japan's weekly leadership contrasts with China/HK weakness.Watch yen/JGB pressure and Hong Kong stabilization; do not infer a fresh Shanghai session.
FuturesNo open Sunday CME equity session at 08:30 CEST.Weekend crypto was nearly flat and is not reliable equity direction.Reassess after Globex opens Sunday evening U.S. time.

Theme dashboards

AI / semis / cloud / power

Quality leadership, financing scrutiny

  • NVDA ended $233.95, above its cited 20-day average; COHR and CRDO confirmed Friday breakout watches, while MU rejected $1,108 and closed lower.
  • Hyperscaler capex revisions are the key earnings-season chain for GPUs, custom silicon, HBM, optics, networking, power and cooling.
  • Weekend OpenAI criticism adds safety/regulatory risk; it does not alter Monday technical levels.
  • Core risks: 5%+ yields, debt-financed buildouts, AI ROI, export controls, customer concentration, power and cooling bottlenecks.
Quantum · extreme risk

Technology milestones; equity tape says wait

  • IONQ, RGTI, QBTS and QUBT lost 3.8%–9.4% over the five sessions through Friday.
  • IonQ's Superion 256 is orderable with 2027 delivery targeted; roadmap and 300× cost claims are forward-looking, not realized economics. IonQ IR
  • D-Wave's Oct. 28 Qubits Asia conference is a real catalyst, but a conference is not revenue. D-Wave IR
  • Require bookings conversion, cash burn, diluted shares and customer acceptance—not benchmark headlines alone.
Peptide / metabolic biotech

Strong science, damaged small-cap tape

  • VKTX and GPCR lost 15.8% and 23.0% over five sessions; LLY/NVO also weakened.
  • Viking's sponsor-reported VK2735 study showed 16%–19% weight loss at week 21 (p<0.0001 versus baseline/placebo), up to 97% maintenance after every-other-week and 90% after monthly dosing over 12 weeks. It is in Phase 3, not approved. Viking IR
  • Clinical diligence must include estimand, discontinuations, GI/safety detail, long-duration durability, CMC, cash runway and financing.

Ranked ideas · paper-tracking only

Sunday rule: all levels are Friday references, not standing orders. Monday gaps can bypass every level. Confidence scores evidence quality—not probability of profit. Fewer ideas are better: two conditional bullish setups, two avoids and five watches.

Bullish / constructive

#1 Conditional bullish

NVDA — NVIDIA

NASDAQ · mega-cap AI platform · high risk

Classification: trend continuation, uncertain direction after Friday's fade. Applicable horizon: day trade and 1–4 weeks; staged 3–12+ months only.

Thesis / catalystAI compute/networking demand and approaching hyperscaler earnings; Friday set a 20-day intraday high.
Evidence / counterargument$233.95 close, +1.34%, volume previously calculated at 1.24× recent average. Counter: rejected $237.88 and 10Y remains 5.28%.
Entry / confirmationHold $233.60 then close above $237.88 with semiconductor/connectivity breadth; prefer a controlled retest over an opening gap.
Invalidation / downsideDay close below $230; swing close below roughly $223.79. Long-term: material estimate cuts, export damage or margin erosion.
Fundamental / valuation lensCategory leadership and earnings momentum support quality; elevated expectations and rates can compress multiples. NVIDIA results
Key risksAI ROI, China/export controls, TSMC/packaging, hyperscaler concentration, custom silicon, power and regulatory shocks.
#2 Conditional bullish

COHR — Coherent

NYSE · large-cap photonics · very high risk

Classification: breakout follow-through only after digestion; direction uncertain. Applicable horizon: day and 1–4 weeks; staged 3–12+ months.

Thesis / catalystScale-out AI requires optical links; Friday confirmed the prior breakout watch at $337.04.
Evidence / counterargument+5.59% Friday on 1.26× recent volume and +13.9% in five sessions. Counter: roughly 13% above the cited 20-day average and no new company release explaining Friday.
Entry / confirmationHold $332.86–$338 on a retest or close above $338.36 with continued volume. Do not chase a gap.
Invalidation / downsideClose below $319, then $315.43; swing thesis fails below roughly $298.22.
Fundamental / valuation lensOptical demand is favorable, but verify orders, margin conversion, leverage and customer concentration. Coherent IR
Key risksMomentum reversal, optical cyclicality, leverage, integration, customer concentration and valuation.

Bearish / short / avoid

#1 Avoid chase · not a short

IONQ / QBTS / RGTI / QUBT

NYSE/Nasdaq · small/mid-cap, mostly pre-profit · extreme risk

Classification: tactical avoid; direction highly uncertain. Applicable horizon: day and 1–4 weeks; 3–12+ months only as venture-risk exposure. No borrow availability or fee claim.

Thesis / catalystFriday relative weakness and five-session losses despite a risk-on close; D-Wave's Oct. 28 event is the next verified basket catalyst.
Evidence / counterargumentFive-session losses: IONQ −3.76%, RGTI −8.46%, QBTS −9.42%, QUBT −8.71%. Counter: contracts, benchmarks or funding can gap shares higher.
Entry / confirmationNo naked short. Avoid strengthens below Friday lows: $43.15 / $15.74 / $15.15 / $8.11.
Invalidation / downsideReconsider avoid on volume-backed closes above $45.34 / $17.00 / $16.11 / $8.76. Any short can lose without limit.
Fundamental lensDemand audited revenue, bookings conversion, customer acceptance, cash burn and fully diluted share counts.
Key risksDilution, roadmap slippage, tiny revenue bases, modality competition, government-contract conditions, liquidity and squeezes.
#2 Avoid falling knife

VKTX / GPCR — clinical obesity developers

NASDAQ · clinical-stage small/mid-cap biotech · extreme/binary risk

Classification: avoid pending stabilization, not a short. Applicable horizon: day and 1–4 weeks; speculative 3–12+ months only after clinical/financing diligence.

Thesis / catalystPeptide/metabolic optionality is real, but the market rejected it: VKTX −15.8% and GPCR −23.0% in five sessions.
Evidence / counterargumentVKTX $29.94 below ~$32.88 20-day average; GPCR $27.67 below ~$36.37. Counter: positive data, partnership or financing can cause discontinuous upside.
Entry / confirmationNo long until VKTX reclaims $31.09 then $32.88, or GPCR reclaims $29.25 and forms a higher low. No naked biotech short.
Invalidation / downsideAvoid weakens on verified favorable clinical/regulatory evidence plus sustained volume-backed reclaims; failure downside can approach cash value.
Biotech evidenceVK2735 sponsor topline includes strong efficacy/maintenance statistics, but Phase 3, long-duration safety, CMC and approval remain unresolved.
Key risksBinary endpoints, tolerability, differentiation versus Lilly/Novo, financing, dilution, CMC, regulation and overnight gaps.

Watchlist — no active entry

#1 Memory

MU — Micron

NASDAQ · large-cap cyclical semiconductor · high risk. Classification: failed-breakout watch. Applicable horizon: day, 1–4 weeks; conditional 3–12+ months. Thesis/catalyst: FY26 results and HBM demand support the AI memory cycle. Evidence/counter: Friday high $1,108.00 missed $1,108.72 and close $1,074.89 was −2.05%, though above ~$1,025 20-day average. Entry: close above $1,108.72 or stable $1,050–$1,025 retest. Invalidation/downside: close below $1,025, then $1,000. Risks: pricing, oversupply, capex, exports and rate compression. Micron IR

#2 Interconnect

CRDO — Credo Technology

NASDAQ · mid/large-cap connectivity semi · very high risk. Classification: confirmed but extended. Applicable horizon: day and 1–4 weeks. Thesis/catalyst: AI interconnect demand; Friday closed $218.64 on 1.22× volume. Evidence/counter: ~21% above its cited 20-day average; fade from $231.59 shows supply. Entry: hold $211.91–$214.87 or close above $231.59. Invalidation/downside: close below $211.91, then $200. Risks: concentration, competition, rich expectations, inventory and beta. Credo IR

#3 Power / cooling

VRT — Vertiv

NYSE · large-cap infrastructure · high risk. Classification: marginal reclaim. Applicable horizon: 1–4 weeks and 3–12+ months. Thesis/catalyst: rack-density and data-center power demand. Evidence/counter: $252.18 cleared the prior trigger by $0.08, but on only 0.62× volume. Entry: hold $252.10 and clear $254.80 with volume. Invalidation/downside: close below $248.54, then $238. Risks: project timing, working capital, customers, competition, rates and valuation. Vertiv IR

#4 Event

TSLA — Tesla

NASDAQ · mega-cap auto/energy/AI · very high risk. Classification: delivery-to-earnings watch. Applicable horizon: day and 1–4 weeks through Oct. 21; not a fresh long-term call. Thesis/catalyst: Q3 deliveries 486,532 and Oct. 21 earnings. Evidence/counter: +4.65% Friday on 1.48× volume; deliveries do not reveal price/mix, margins or cash flow. Entry: hold $359.41 and close above $374.60; stronger above $386.83. Invalidation/downside: close below $359.41, then $345.88. Risks: margins, autonomy/regulation, execution, competition and valuation. SEC exhibit

#5 Metabolic quality

LLY — Eli Lilly

NYSE · mega-cap pharma · high event risk. Classification: stabilization watch. Applicable horizon: 1–4 weeks and 3–12+ months. Thesis/catalyst: retatrutide Phase 3 efficacy supports franchise optionality. Evidence/counter: sponsor-reported randomized, double-blind TRIUMPH-1 (n=2,339) was strong, but GI events, dysesthesia and 11.3% discontinuation at 12 mg matter; shares are below the cited 20-day average. Entry: reclaim $1,164.92; stronger above $1,215. Invalidation/downside: below $1,136.66 then $1,113.29; long-term on regulatory/safety/CMC setback. Risks: approval, manufacturing, payer access, competition, pricing and valuation. Lilly IR

Changes versus the 2026-10-03 report

Important 7–30 day catalysts

Mon Oct. 5 · 16:00 CEST — U.S. ISM services. Growth, employment and price components after weak payrolls. NY Fed calendar
Tue Oct. 6 · 14:30 CEST — U.S. trade balance; 16:45 CEST Bowman regulation/supervision speech. NY Fed · Fed
Wed Oct. 7 · 20:00 CEST — September FOMC minutes. Key rate-volatility catalyst. Fed
Thu Oct. 8 · 10:30 / 14:30 CEST — Waller economic outlook / initial claims; PepsiCo and Delta are among the week's prominent earnings reporters. Fed · Reuters
Fri Oct. 9 · 16:00 CEST — Preliminary Michigan sentiment. Inflation expectations matter with Brent above $100. NY Fed
Oct. 14–16 — CPI; retail sales/PPI; industrial production/import prices. High-density inflation/growth test. BLS · NY Fed
Wed Oct. 21 — Tesla Q3 earnings. Margins, cash flow, pricing and capex matter more than delivery headlines. Tesla IR
Wed Oct. 28 — FOMC decision/press conference; D-Wave Qubits Asia. Macro and quantum-event risk on the same day. Fed · D-Wave
Thu Oct. 29 — Advance U.S. GDP and PCE. Major growth/inflation combination. NY Fed

Bottom line by horizon

Day trade

Wait for Monday confirmation

NVDA and COHR lead only if Friday levels hold and yields/oil are stable. Avoid opening-gap chases in COHR/CRDO and falling knives in quantum/biotech.

Biggest risk: weekend geopolitical/oil gap. Invalidation: NVDA below $230 or COHR below $319 on a close.

1–4 week swing

Quality AI exposure, smaller sizing

Favor liquid leaders and verified capex beneficiaries; keep exposure controlled while 10Y exceeds 5%. TSLA is event-defined through Oct. 21.

Biggest risk: minutes/CPI/oil revive hike and duration pressure. Invalidation: stated trend levels fail or estimates/capex guidance are cut.

3–12+ month investment

Stage entries; demand economic proof

AI infrastructure merits diligence, not blanket buying. Quantum requires commercial conversion; peptide biotech requires efficacy, safety, CMC, regulatory and runway proof.

Biggest risk: normalized cash flows fail to justify valuations. Invalidation: durable guide cuts, contract slippage, financing stress or regulatory setbacks.

Data quality & source controls

Verified

  • More than five live retrievals covered Reuters market/news, MarketWatch/CNN quotes, Cboe, Treasury/FRED, BLS, NY Fed/Fed calendars, Nasdaq earnings API, SEC/company IR and biotech/quantum primary releases.
  • U.S. closes match Reuters and CNN; global index direction was cross-checked with Reuters, MarketWatch and CNN.
  • VIX is cross-checked against Cboe's official CSV; 2Y/10Y are consistent with Treasury/Reuters.
  • Clinical statistics are sponsor-reported and labeled; they are not treated as peer-reviewed certainty or approval.
  • All individual-stock levels are Friday OHLC/technical references carried from the audited Oct. 3 report because there is no Sunday cash session.

Limitations and failed retrievals

  • CME's quote endpoint returned HTTP 403 and the interactive page failed with an HTTP/2 protocol error. More importantly, the weekly equity-futures session was not open at 08:30 CEST; no “live” U.S. future is claimed.
  • Yahoo chart API returned HTTP 429. Stooq combined-quote URLs returned HTTP 404. Market closes were therefore cross-checked via Reuters, CNN, MarketWatch, Cboe and Treasury rather than invented.
  • Three web-search calls later hit a provider rate limit; direct Reuters, Fed, company-IR and Nasdaq retrievals supplied the needed evidence.
  • Shanghai's 3,842.19 reference is Sept. 30 because mainland markets were closed; no Friday change is inferred.
  • Weekend Bitcoin is continuously traded but can diverge materially from Monday equities. No borrow availability, fee, real-time spread, analyst rating or guaranteed stop execution is claimed.

Clickable source ledger

  1. Reuters Oct. 2 U.S. close — indices, breadth, rate expectations and notable moves.
  2. Reuters global close — global equities, rates, FX, oil and gold.
  3. Reuters week ahead — yields, Q3 earnings expectations, AI capex and early reporters.
  4. BLS Employment Situation; Treasury curve; Cboe VIX CSV.
  5. Federal Reserve calendar; NY Fed October indicators.
  6. Reuters OpenAI safety report.
  7. IonQ Superion primary release; D-Wave Oct. 28 event.
  8. Viking VK2735 primary results; Lilly retatrutide primary results.
  9. Tesla SEC exhibit; Micron results; NVIDIA results.